Abstract: Provided herein are long lasting hair compositions, color enhancers, and markers for selecting the same.

Abstract: An optical system with aberration correction is disclosed. The optical system may include an illumination source. The optical system may include a detector. The optical system may include one or more collection optics configured to image a sample onto the detector based on illumination from the illumination source. The optical system may include two or more aberration correction plates located in one or more pupil planes of the one or more collection optics. The two or more aberration correction plates may provide at least partial correction of two or more linearly-independent aberration terms. Any particular one of the two or more aberration correction plates may have a spatially-varying thickness profile providing a selected amount of correction for a single particular aberration term of the two or more linearly-independent aberration terms.

Abstract: In one aspect, a computerized method for determining a probability value that a real-estate asset is to be placed on the market for sale includes the step of obtaining a database of real-estate assets. The method includes the step of merging a set of similar near real-estate tracts using a breadth-first search. The method, includes the step of creating a submarket of real-estate assets by performing duster analysis with a hierarchal-clustering method in a county context. The method includes the step of identifying a set of datasets of real-estate assets on a per-county level. The method includes the step of identifying a set of datasets of real-estate assets on a per-state level. The method includes the step of determining a probability that each real-estate asset will be placed for sale based on a set of geo-models. The method includes the step of mapping the probability that each real-estate asset will be placed for sale to a score.

Abstract: Disclosed herein are methods for preparing [1,2,4]triazolo[4,3-a]pyridines, particularly (R)-6-(1-(8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, and precursors thereof, such as a method comprising reacting (R)—N-(3-fluoro-5-(1methyl-1H-pyrazol-4-yl) pyridin-2-yl)-2-(3-(2-methoxyethoxy)-5-oxo-1,6-naphthyridin-6(5H)yl) propanehydrazide (“HYDZ”): (HYDZ) under conditions sufficient to form (R)-6-(1-(8-fluoro-6-(1-methyl-IH-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (“A”): (A)

Abstract: Disclosed herein are methods for preparing [1,2,4]triazolo[4,3-a]pyridines, particularly (R)-6-(1-(8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, and precursors thereof, such as a method comprising reacting (R)—N-(3-fluoro-5-(1methyl-1H-pyrazol-4-yl) pyridin-2-yl)-2-(3-(2-methoxyethoxy)-5-oxo-1,6-naphthyridin-6(5H)yl) propanehydrazide (“HYDZ”): (HYDZ) under conditions sufficient to form (R)-6-(1-(8-fluoro-6-(1-methyl-IH-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (“A”): (A)

Abstract: In one aspect, a method of generating a prediction list of real-estate assets that have a specified probability of being placed for sale within a specified period of time includes the step of providing a list of real-estate assets. Each real-estate asset is associated with one or more real-estate assets attributes. The method includes the step of providing a training data set wherein the training data set comprises a past population of data associated with a plurality of real-estate assets and a set of training-data set attributes for each real-estate asset in the plurality of real-estate assets. The method includes providing a testing data set wherein the testing data set comprises another past population of data associated with the plurality of real-estate assets and a set testing-data set attributes for each real-estate asset in the plurality of real-estate assets, wherein the set of testing data set attributes comprises an updated version of the training data set attributes from a specified later time.

Abstract: Various disclosed embodiments include methods and systems for configuration and management of an electronic control unit (ECU). According to disclosed embodiments, a method for configuration and management of an ECU includes receiving by a data processing system at least one calibration parameter and a corresponding value for the ECU and generating by the data processing system virtual memory locations representing physical memory locations of the ECU. The method includes receiving by the data processing system allocations for the virtual memory locations, wherein the allocations identify blocks and sub-blocks allocated to the calibration parameter and the corresponding value. The method includes generating and storing by the data processing system an output responsive to the allocations, wherein the output contains a memory layout of the stored parameter and the value, and wherein the output is configured to be stored in the physical memory locations of the ECU.

Abstract: An electron donor composition comprising a dihydroanthracene derivative and a phthalate ester. Furthermore, a solid catalyst composition comprising the electron donor composition for use in ?-olefin polymerisation. Further, a process for the production of a polymer containing ?-olefin monomer units with the electron donor composition.

Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3? and GSK3? polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.

Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3? and GSK3? polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.

Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3? and GSK3? polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.